Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

CeriBell, Inc. (Nasdaq: CBLL), a pioneering medical technology company specializing in the diagnosis and management of serious neurological conditions, has announced it will release its financial results for the fourth quarter and full year of 2025 following the market close on February 24, 2026. The company will host a conference call on the same day at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. Interested parties can participate by calling (800) 715-9871 for domestic calls or (646) 307-1963 for international calls, using access code 9394689. Additionally, a live and archived webcast of the call will be accessible in the "Investor Relations" section of Ceribell's website.

Ceribell is noted for its innovative Ceribell System, a unique point-of-care electroencephalography (EEG) platform designed to cater to the critical needs of patients in acute-care environments. This system merges portable, rapidly deployable hardware with advanced artificial intelligence algorithms to facilitate quick diagnosis and continuous monitoring of neurological conditions. The Ceribell System is FDA-cleared for detecting seizures and delirium in hospitals' intensive care units and emergency departments across the U.S.

As a company headquartered in Sunnyvale, California, Ceribell is committed to revolutionizing how healthcare providers diagnose and manage patients with complex neurological issues. Investors and interested parties looking for more information about CeriBell can visit their website or follow the company on social media platforms such as LinkedIn. Investors seeking further details can contact the Gilmartin Group through the provided email addresses.

As CeriBell, Inc. (Nasdaq: CBLL) approaches the announcement of its fourth quarter and full year 2025 financial results on February 24, 2026, investors should prepare for a pivotal moment in the company’s trajectory. The financial data released will provide invaluable insights into the company’s performance and growth potential, particularly important for a firm positioned in the rapidly evolving medical technology sector focused on neurology.

CeriBell’s development of a point-of-care electroencephalography (EEG) system reflects a substantial innovation in acute care settings, catering to a growing need for rapid and effective diagnosis of neurological conditions. The fact that the Ceribell System is FDA-cleared for detecting seizures and delirium in intensive care and emergency rooms enhances its market credibility and positions it as a valuable asset in critical healthcare environments. Investors should closely monitor revenue growth from product sales, along with any announced partnerships or contracts that could widen market access.

It will also be crucial to evaluate operating expenses and R&D investments indicated in the upcoming earnings call. The medical tech market is highly competitive, and a sustainable profit margin will depend on how efficiently CeriBell can translate its innovations into practical applications while managing costs.

Furthermore, commentary from management regarding the adoption rates and feedback from healthcare providers will be telling. If the product demonstrates promising traction, it could signal an attractive growth opportunity, potentially driving stock performance post-announcement.

As a strategy, investors may want to position themselves ahead of the earnings release while staying vigilant for price fluctuations following the announcement. Engaging with the live conference call may provide additional context that can assist in refining investment strategies. Holding long-term, while also being open to short-term trading, may provide the balance needed in this high-growth sector.